Eli Lilly and Company (NYSE: LLY) Q1 2026 Financial Results Summary

Release Date: April 30, 2026

Eli Lilly and Company has reported its financial results for the first quarter of 2026, showcasing substantial growth in revenue and earnings in comparison to the same period of the previous year. Here is a summary of the key highlights:

Financial Performance

• Revenue:
  • Q1 2026 revenue reached $19.8 billion, an increase of 56% from $12.7 billion in Q1 2025.
  • Key Products revenue grew to $13.4 billion, up 160% from the same quarter last year.
• Earnings Per Share (EPS):
  • Reported EPS for Q1 2026 was $8.26, representing a 170% increase versus $3.06 in Q1 2025.
  • Non-GAAP EPS for Q1 2026 increased by 156% to $8.55, compared to $3.34 in Q1 2025.
• Net Income:
  • Net income reported was $7.4 billion, up 168% from $2.8 billion in Q1 2025.
  • Non-GAAP net income was $7.7 billion, an increase of 155% compared to $3.0 billion in Q1 2025.
• Gross Margin:
  • Increased to $16.2 billion, up 54% from $10.5 billion in Q1 2025. Gross margin percentage decreased to 81.9%, down 0.6 percentage points from last year.
• Research and Development Expenses:
  • Increased by 28% to $3.5 billion, making up 18% of revenue.
• Marketing, Selling, and Administrative Expenses:
  • Rose by 19% to $2.9 billion, primarily due to promotional efforts for ongoing and planned launches.

Key Revenue Drivers

• Mounjaro Revenue:
  • Increased 125% to $8.7 billion.
  • U.S. revenue rose by 59% to $4.2 billion.
• Zepbound Revenue:
  • Grew 80% to $4.2 billion in the U.S. from $2.3 billion in Q1 2025.
• International Revenue:
  • Revenue outside the U.S. grew by 81% to $7.7 billion, primarily driven by volume growth.

Business Developments

• Regulatory Progress:
  • FDA approved Foundayo (orforglipron) for adults with obesity or weight-related medical issues.
• Pipeline Success:
  • Positive Phase 3 results for Foundayo in treating type 2 diabetes and obesity, Jaypirca for CLL or SLL, Taltz, and Zepbound for psoriasis, and retatrutide in type 2 diabetes.
• Acquisitions:
  • Agreements to acquire Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics to bolster future growth.

Guidance Adjustments

• Updated 2026 Guidance:
  • Revenue: Increased to a range of $82.0 billion to $85.0 billion from a prior estimate of $80.0 billion to $83.0 billion.
  • Non-GAAP EPS Guidance: Increased to a range of $35.50 to $37.00 from $33.50 to $35.00.

Dividend and Share Repurchase

• Dividend:
  • The company declared a quarterly dividend of $1.73 per share, representing a 15% increase from $1.50 in Q1 2025.

Summary Metrics Comparison

Note: All amounts are in billions.

Metric	Q1 2026	Q1 2025	% Change
Revenue	$19.8 billion	$12.7 billion	56%
Net Income	$7.4 billion	$2.8 billion	168%
Reported EPS	$8.26	$3.06	170%
Non-GAAP EPS	$8.55	$3.34	156%
Gross Margin (%)	81.9%	82.5%	-0.6pp
R&D Expenses	$3.5 billion	$2.7 billion	28%
Marketing, Selling & Admin Exp.	$2.9 billion	$2.5 billion	19%

Eli Lilly and Company’s robust results in Q1 2026 indicate a promising trajectory, supported by significant product growth, critical regulatory approvals, and strategic acquisitions aimed at advancing its therapeutic portfolio.

Here are the extracted tables in HTML format:

Condensed Consolidated Statements of Income

Note: All amounts are in millions.

Condensed Consolidated Balance Sheets

Note: All amounts are in millions.

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.